Handelsbanken Fonder
MRNA icon

Handelsbanken Fonder’s Moderna MRNA Stock Holding History

Handelsbanken Fonder’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.99M Buy
114,100
+2,500
+2% +$129K 0.02% 413
2026
Q1 		$5.67M Buy
111,600
+9,800
+10% +$457K 0.02% 460
2025
Q4 		$3M Sell
101,800
-1,100
-1% -$29.9K 0.01% 612
2025
Q3 		$2.66M Buy
102,900
+10,100
+11% +$282K 0.01% 641
2025
Q2 		$2.56M Sell
92,800
-62,447
-40% -$1.64M 0.01% 580
2025
Q1 		$4.4M Sell
155,247
-1,723
-1% -$61.1K 0.02% 444
2024
Q4 		$6.53M Buy
156,970
+36,697
+31% +$1.75M 0.02% 411
2024
Q3 		$8.04M Buy
120,273
+1,440
+1% +$132K 0.03% 382
2024
Q2 		$14.1M Sell
118,833
-7,388
-6% -$935K 0.06% 273
2024
Q1 		$13.4M Buy
126,221
+10,393
+9% +$1.05M 0.06% 294
2023
Q4 		$11.5M Sell
115,828
-89,169
-43% -$7.5M 0.06% 304
2023
Q3 		$21.2M Buy
204,997
+5,233
+3% +$584K 0.12% 188
2023
Q2 		$24.3M Sell
199,764
-34,192
-15% -$4.56M 0.13% 177
2023
Q1 		$35.9M Sell
233,956
-1,648
-0.7% -$272K 0.21% 110
2022
Q4 		$42.3M Buy
235,604
+18,854
+9% +$3.08M 0.27% 87
2022
Q3 		$25.6M Sell
216,750
-7,814
-3% -$1.19M 0.17% 145
2022
Q2 		$32.1M Buy
224,564
+10,242
+5% +$1.46M 0.21% 114
2022
Q1 		$36.9M Buy
214,322
+74,221
+53% +$12.5M 0.21% 114
2021
Q4 		$35.6M Buy
140,101
+13,613
+11% +$3.98M 0.18% 134
2021
Q3 		$48.7M Buy
126,488
+12,490
+11% +$4.61M 0.26% 89
2021
Q2 		$26.8M Sell
113,998
-31,936
-22% -$5.71M 0.14% 160
2021
Q1 		$19.1M Buy
145,934
+19,759
+16% +$2.86M 0.11% 190
2020
Q4 		$13.2M Buy
126,175
+74,870
+146% +$7.57M 0.08% 241
2020
Q3 		$3.63M Buy
51,305
+15,900
+45% +$1.11M 0.03% 427
2020
Q2 		$2.27M Buy
+35,405
New +$1.94M 0.02% 500

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Handelsbanken Fonder's MRNA Position: Q2 2026 in Review

Handelsbanken Fonder increased its Moderna (MRNA) stake by 2.2% in Q2 2026, buying an estimated $129K and bringing the position to 114,100 shares worth $7.99M. The position accounts for 0.02% of the portfolio, ranked #413.

Handelsbanken Fonder first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $48.7M in Q3 2021. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Handelsbanken Fonder held 114,100 shares of Moderna worth $7.99M as of Q2 2026.
  • Handelsbanken Fonder bought 2,500 Moderna shares in Q2 2026, an estimated $129K.
  • Moderna made up 0.02% of Handelsbanken Fonder's portfolio in Q2 2026, its #413 holding.
  • Handelsbanken Fonder first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Handelsbanken Fonder's Moderna position peaked at $48.7M in Q3 2021.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.